Sofia Spampinato

Sofia Spampinato

Auto-generated profile, based on publicly available information

Sofia Spampinato

Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SSSofia Spampinato
Sofia Spampinato
LFLars U. Fokdal
Lars U. Fokdal
RPRichard Pötter
Richard Pötter
CHChristine Haie-Meder
Christine Haie-Meder
JLJacob C. Lindegaard
Jacob C. Lindegaard
KTKari Tanderup
Kari Tanderup

1 March 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SSSofia Spampinato
Sofia Spampinato
NJNina B K Jensen
Nina B K Jensen
RPRichard Pötter
Richard Pötter
LFLars U Fokdal
Lars U Fokdal
CCCyrus Chargari
Cyrus Chargari
KTKari Tanderup
Kari Tanderup

1 May 2021 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SSSofia Spampinato
Sofia Spampinato
LFLars U. Fokdal
Lars U. Fokdal
RPRichard Pötter
Richard Pötter
CHChristine Haie-Meder
Christine Haie-Meder
JLJacob C. Lindegaard
Jacob C. Lindegaard
KTKari Tanderup
Kari Tanderup

30 January 2023 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SSSofia Spampinato
Sofia Spampinato
KTKari Tanderup
Kari Tanderup
JLJacob C. Lindegaard
Jacob C. Lindegaard
MSMaximilian P. Schmid
Maximilian P. Schmid
ASAlina Sturdza
Alina Sturdza
KKKathrin Kirchheiner
Kathrin Kirchheiner
To quantify the association of persistent morbidity with different aspects of quality of life (QOL) in locally advanced cervical cancer (LACC) survivors. Longitudinal outcome from the EMBRACE-I study was evaluated. Patient-reported symptoms and QOL were prospectively scored (EORTC-C30/CX24) at baseline and regular follow-ups. Physician-assessed symptoms were also reported (CTCAEv.3). Persistent symptoms were defined if present in at least half of the follow-ups. QOL items were linearly transformed into a continuous scale. Linear mixed-effects models (LMM) were applied to evaluate and quantify the association of persistent symptoms with QOL. Overall QOL deterioration was evaluated by calculating the integral difference in QOL over time obtained with LMM for patients without and with persistent symptoms. Out of 1416 patients enrolled, 741 with baseline and ≥ 3 late follow-ups were analyzed (median 59 months). Proportions of persistent EORTC symptoms ranged from 21.8 % to 64.9 % (bowel control and tiredness). For CTCAE the range was 11.3-28.6 % (limb edema and fatigue). Presence of any persistent symptom was associated with QOL, although with varying magnitude. Role functioning and Global health/QOL were the most impaired aspects. Fatigue and pain showed large differences, with reductions of around 20 % for most of the QOL aspects. Among organ-related symptoms, abdominal cramps showed the largest effect. Persistent symptoms are associated with QOL reductions in LACC survivors. Organ-related symptoms showed smaller differences than general symptoms such as fatigue and pain. In addition to optimizing treatment to minimize organ-related morbidity, effort should be directed towards a more comprehensive and targeted morbidity management.

1 April 2020 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SSSofia Spampinato
Sofia Spampinato
KTKari Tanderup
Kari Tanderup
EMEdvard Marinovskij
Edvard Marinovskij
SASusanne Axelsen
Susanne Axelsen
EPErik M. Pedersen
Erik M. Pedersen
LFLars Fokdal
Lars Fokdal

15 September 2025 in Acta Oncologica
Verified
Journal Article
Open access
PDF file
KSKatrine Smedegaard Storm
Katrine Smedegaard Storm
KSKaren-Lise Spindler
Karen-Lise Spindler
GPGitte F. Persson
Gitte F. Persson
CBClaus Behrens
Claus Behrens
PSPatrik Sibolt
Patrik Sibolt
ESEva Serup-Hansen
Eva Serup-Hansen
Background and purpose: Treatment-related diarrhea is a challenge for patients treated with chemo-radiotherapy (CRT) for anal cancer in a curative setting. This study aims to investigate dosimetric and clinical predictors of acute and late diarrhea for patients treated with CRT or radiotherapy (RT) alone for anal cancer. Additionally, to investigate different bowel contouring methods ability to predict diarrhea. Patient/material and methods: Patients treated with CRT or RT alone in the prospective, observational DACG-I Plan-A study (2015–2021) were included. Toxicity endpoints were acute grade ≥2 diarrhea, and late grade ≥1 diarrhea recorded at 1 year after treatment (Common Terminology Criteria of Adverse Events (CTCAE), v4.0). Bowel volumes were contoured on the planning computed tomography (CT) as bowel cavity, bowel bag, individual bowel loops, and terminal ileum. Dosimetric variables included V15Gy, V30Gy, and V45Gy for the different bowel volumes. Clinical variables included tumor size, N-stage, and chemotherapy regimen. Logistic regression was used to evaluate the association between variables and toxicity. Results: Of the 290 patients included in this study, 116 (40%) experienced acute grade ≥2 diarrhea, and 56 of 256 (22%) had late grade ≥1 diarrhea. Patients treated with 5-FU/Capecitabine had a threefold higher risk of acute diarrhea compared to those receiving weekly Cisplatin or RT alone (p < 0.001). A trend indicating an increased risk of acute grade ≥2 diarrhea for patients with larger bowel volumes receiving radiation was observed. This was most pronounced for bowel bag V30Gy (p = 0.09); however, results from the different bowel contouring methods were similar. No parameters were predictive of late diarrhea. Interpretation: No dosimetric or clinical predictors of late diarrhea were found and only a trend was found between higher dose to bowel and risk of acute diarrhea. Treatment with 5-FU/Capecitabine showed a notable association with acute diarrhea. No contouring method was superior in predicting diarrhea.